Is Boston Scientific Corp. (BSX) Positioned for Solid, Durable Growth?

2 hours ago 2

Soumya Eswaran

Tue, December 23, 2025 astatine 7:05 AM CST 3 min read

Parnassus Investments, an concern absorption company, released the “Parnassus Core Equity Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The S&P 500 Index surged successful the 3rd quarter, driven by capitalist optimism that grew connected expectations of monetary easing, beardown user demand, and coagulated firm earnings. The Fund (Investor Shares) returned 2.57% (net of fees) successful the quarter, trailing the S&P 500 Index’s 8.12% return. YTD, the money returned 9.89% compared to 14.83% for the index. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Parnassus Core Equity Fund highlighted stocks specified arsenic Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) manufactures and markets aesculapian devices that run successful the MedSurg and Cardiovascular segments. The one-month instrumentality of Boston Scientific Corporation (NYSE:BSX) was -4.86%, and its shares gained 5.89% of their worth implicit the past 52 weeks. On December 22, 2025, Boston Scientific Corporation (NYSE:BSX) banal closed astatine $96.43 per share, with a marketplace capitalization of $142.952 billion.

Parnassus Core Equity Fund stated the pursuing regarding Boston Scientific Corporation (NYSE:BSX) successful its 3rd 4th 2025 capitalist letter:

"We made lone a fewer important moves successful the quarter. In the Health Care sector, we trimmed Eli Lilly and Stryker, utilizing the proceeds to initiate a presumption successful Boston Scientific Corporation (NYSE:BSX), an innovative aesculapian instrumentality shaper with important maturation drivers. Boston Scientific’s first-mover advantage, robust objective information and heavy relationships with physicians let it to support ascendant marketplace stock and outgrow competitors, with further maturation drivers similar Watchman and Farapulseto assistance it grow rapidly successful underpenetrated markets. Management, led by CEO Mike Mahoney, has transformed the institution done disciplined R&D and M&A, driving integrated income maturation and borderline expansion. With accordant execution, expanding margins and planetary request tailwinds, Boston Scientific is good positioned for durable growth."

Was Jim Cramer Right About Boston Scientific Corporation (BSX)?

Boston Scientific Corporation (NYSE:BSX) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 102 hedge money portfolios held Boston Scientific Corporation (NYSE:BSX) astatine the extremity of the 3rd quarter, compared to 100 successful the erstwhile quarter. Boston Scientific Corporation (NYSE:BSX) announced that its consolidated gross for the 3rd 4th of 2025 reached $5.065 billion, indicating a 20.3% maturation compared to Q3 2024. While we admit the imaginable of Boston Scientific Corporation (NYSE:BSX) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.